Dr. Michael Henderson, serving as the Chief Executive Officer and Director of Apogee Therapeutics, receives a total annual compensation package valued at approximately $1.29 million. This comprehensive executive remuneration structure comprises a base salary of roughly $700,000, alongside performance-based bonuses, stock options, and equity incentives aligned with corporate development milestones and overall market compensation standards for clinical-stage biotechnology executives.